GameStop Corp. vs uniQure N.V. Ordinary Shares — how do they compare? GameStop Corp. trades at $26.7 (market cap $13.73B), while uniQure N.V. Ordinary Shares trades at $20.78 (market cap $1.48B). The key difference: GameStop Corp. is far larger — about 9.3× uniQure N.V. Ordinary Shares's market cap, and GameStop Corp. is trading nearer its 52-week high, uniQure N.V. Ordinary Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold GameStop Corp. for 62 Days and uniQure N.V. Ordinary Shares for 0 Days on average.
| GME | QURE | |
|---|---|---|
Market Cap | $13.73B | $1.48B |
Volume | 12,710,661 | 2,488,780 |
Sector | Consumer Cyclical | Health |
52-Week High | $27.23 | $70.59 |
52-Week Low | $17.87 | $9.03 |
Typical Hold Time | 62 Days | 0 Days |
Enterprise Value | $13.01B | $728.62M |
Signals from Pluang's Aura AI — not financial advice
GME trades at $27.15, down 0.29% on the day, with a bullish technical signal supported by moving averages. The company reported net income of $131.3M in 2025, a significant turnaround from prior losses, and holds a strong cash position of $4.77B. Recent insider buying by CEO Ryan Cohen has driven positive sentiment, with shares gaining 31% over the past month.
The outlook is mixed; strong cash reserves and insider confidence support upside, but revenue declined to $3.82B in 2025, and analyst consensus remains cautious with only 16.7% buy ratings. Key risks include execution challenges in the retail gaming sector and high valuation multiples relative to historical performance.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Global Market Group Ltd. operates an Internet website that connects Chinese manufacturers with international buyers. The Company's customers can post company profiles and product information in standardized formats; post product listings; and trade leads.
Read more on GME →uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →